Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind double-dummy multicenter trial of KH607 versus vortioxetine in major depressive disorder
CTR20262786Phase 3Active
- Sponsor
- Chengdu Kanghong Pharmaceutical Group
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of KH607 in major depressive disorder (MDD), sponsored by Chengdu Kanghong Pharmaceutical Group. Started Jul 2026; status: active.
02
Drugs
KH607
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on CTR20262786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262786.